Vycor Medical, Inc. (OTCQB: VYCO) reported financial results for the three months ended March 31, 2026, showing a 5% increase in revenue to $458,540 compared to $436,378 in the same period of 2025. The company attributed the growth primarily to its Vycor Medical division, which generated $440,441 in revenue, driven by international markets. The operating profit improved to $45,808 from an operating loss of $(12,806) in the prior year, while non-GAAP operating profit rose to $59,788 from $20,388.
The company operates two business units: Vycor Medical, which manufactures the ViewSite™ Brain Access System (VBAS) for neurosurgery, and NovaVision®, which offers vision rehabilitation therapies for stroke and brain injury patients. The VBAS unit saw revenue increase 5% year-over-year, with most growth coming from international sales, a key company strategy. NovaVision, still in development, contributed $18,099 in revenue, slightly up from $17,858 in 2025.
During the first quarter of 2026, two new peer-reviewed studies on VBAS were published, bringing the total number of published peer-reviewed clinical papers to 52, with an additional 14 other clinical papers. One study focused on a complex pediatric tumor case, highlighting the effectiveness of integrating neuro-navigation systems with VBAS as “a paramount strategy for the surgical resection” of such lesions. The second study, a retrospective analysis of 23 patients undergoing tumor resection, compared outcomes using VBAS with traditional blade retractors. The study found significantly fewer new neurological deficits at follow-up for the tubular retractor group, implying safer tumor resection with VBAS.
Gross profit for the Vycor Medical division increased to $359,040, with a gross margin of 82%, consistent with the prior year. NovaVision reported a gross margin of 89%, down from 94% in 2025. Non-GAAP cash operating expenses decreased to $315,365 from $338,146, contributing to the improved operating profit.
On a GAAP basis, the company reported an operating profit of $45,808, a net loss of $142,077, or $0.00 per share, after preferred stock dividends. Non-GAAP net loss, which excludes non-cash depreciation and stock-based compensation, was $128,097, or $0.00 per share. Management uses non-GAAP measures to evaluate period-to-period performance, believing they provide investors additional insight into core business operations.
The results underscore the company’s progress in expanding its international footprint and validating its technology through clinical evidence. The VBAS system, FDA-cleared and used in over 350 U.S. hospitals and internationally, is protected by 49 issued and 8 pending patents. NovaVision’s Visual Restoration Therapy (VRT) remains the only FDA-cleared therapy for vision rehabilitation after neurological brain damage, though it requires further development to reach its market potential.
For more information, visit the company’s websites at www.vycormedical.com, www.vycorvbas.com, or www.novavision.com.
